NeuroMetrix Stock Surges As Its Nerve Stimulator Scores FDA Breakthrough Designation For Fibromyalgia

• NeuroMetrix Inc's (NASDAQ: NURO) Quell device has received Breakthrough Designation from the FDA to treat fibromyalgia symptoms in adults.

• Fibromyalgia is a common form of chronic pain accompanied by fatigue, sleep, cognitive and mood disturbances.

• Quell is a wearable electrical nerve stimulator. It utilizes position and motion sensing to automatically adjust stimulation for an optimal patient experience both day and night.

• The data submitted by NeuroMetrix in support of the Breakthrough Designation included results of 119 subjects.

• In an intention-to-treat (ITT) analysis of all subjects, 56% of those on active treatment exhibited a clinically meaningful improvement in health-related quality-of-life compared to 35% that received sham therapy.

• The Company expects to launch Quell for fibromyalgia in the second half of 2022.

• Price Action: NURO shares jump 43.9% at $4.69 during the market session on the last check Tuesday.

• Related content: Benzinga's Full FDA Calendar.

See more from Benzinga

• Click here for options trades from Benzinga

• Drug Distributors To Pay Up To .1B To Settle New York Opioid Claims

• Pacific Biosciences To Buy DNA Sequencing Firm For Up To 0M, Announces 0M Capital Raise For Deal Funding

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.